Familial hypercholesterolemia (FH) is a genetic and hereditary disorder, which leads to a high level of LDL (bad) cholesterol. The condition begins at birth and can cause heart attacks at an early age.
The total prevalent population of Familial Hypercholesterolemia in the seven major markets was found to be 2,367,466 in 2017. However, the total diagnosed prevalent patient population of FH was 965,405 in 2017. The diagnosed prevalence of Familial Hypercholesterolemia was found to be 244,214 in the United States in 2017.
DelveInsight's "Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Familial Hypercholesterolemia Market, historical and forecasted epidemiology, the pipeline insight as well as the Familial Hypercholesterolemia market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Familial Hypercholesterolemia Market Analysis
The Familial Hypercholesterolemia market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Familial Hypercholesterolemia market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Familial Hypercholesterolemia market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Familial Hypercholesterolemia Treatment Market
Early diagnosis and treatment of Familial Hypercholesterolemia are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of treatment is to reduce LDL-C by 50% from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation.
Familial Hypercholesterolemia Epidemiology Forecast
The Familial Hypercholesterolemia epidemiology section covers insights about historical and current Familial Hypercholesterolemia patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Familial Hypercholesterolemia Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Familial Hypercholesterolemia Pipeline Analysis
The Familial Hypercholesterolemia Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched in the market during the study period. The analysis covers the Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and drug sales.
Familial Hypercholesterolemia market size is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options. The familial Hypercholesterolemia pipeline is robust and possesses multiple potential drugs in late and mid-stage developments to be launched in the near future.
Familial Hypercholesterolemia Companies operating in the market:
Regeneron Pharmaceuticals
Novartis
LIB Therapeutics
NeuroBo Pharmaceuticals
Madrigal Pharmaceuticals
Jiangsu HengRui Medicine
And many others.
Familial Hypercholesterolemia Therapies covered in the report include:
Evinacumab (REGN1500)
Inclisiran
LIB003
Gemcabene
SHR-1209
And many more.
For more details, visit: Familial Hypercholesterolemia Market Trends